



JUVELOOK & LENISNA
A RANGE OF NEW GENERATION COLLAGEN INDUCTORS
PDLA + HA

SKIN AGEING

COLLAGEN & ELASTIN

Over the years, the skin undergoes changes that gradually affect all its layers

From 20 : Skin begins to experience oxidative stress and irregular hydration, while from age 25, collagen production gradually declines : from -1% to 1,5% of collagen production every year.

From 30 : Skin recovery slows down, with dullness, uneven texture, and early signs of aging


From 40 : skin tissue loses structure and becomes thinner, with deeper wrinkles and loss of facial contour definition.

It is due to increasing loss of collagen & elastin with slower production

COLLAGEN - KEY ROLE IN SKIN AGEING

■ 70 to 80% of the skin composition

--> Entanglement with elastin, essential for the skin firmness & elasticity



> TARGET THE STRUCTURAL CAUSES OF AGEING TO RESTORE YOUTHFUL APPEARANCE
DIFFERENTS STIMULATING WAYS OF COLLAGEN & ELASTIN

- Activation & induction of pathways for collagen and elastin production
- Activation of fibroblasts
- Ideal environment & nutrients

JUVELOOK & LENISNA

THE NEW ERA OF COLLAGEN INDUCTORS

NEW GENERATION TECHNOLOGY TO STIMULATE COLLAGEN FROM WITHIN
PDLLA + HA

EXCELLENT SAFETY PROFILE & EFFICACY
 High tissue biocompatibility | Strong tissue & collagen stimulation

RANGE OF **COLLAGEN INDUCTORS**

To adapt ageing and patient concerns with natural & gradual results
 Multilayering approach : Dermis and subcutaneous tissue



REFINE & TIGHTEN

To improve skin texture
 For face, neck and décolletage

CONTOUR & LIFT

For restoration of volume & improve skin firmness - for face and body

Concentration	50 mg PDLLA 42.5mg + HA 7.5mg	170 mg PDLLA 170 mg + HA 30 mg
PDLLA particule size	● ● ● ●	● ● ● ●
Collagen stimulation	● ● ● ●	● ● ● ●
Injection layer	Deep dermis	Subcutaneous

CE marked
 CLASS III

#1,5M of vials sold
 worldwide since 2017 *

* Internal datas – May 2025

PDLLA + HA CARRIER

CONTROLLED COLLAGEN INDUCTION & **DISPERSIBLE**


85% PDLLA (POLY-D,L-LACTIC ACID)

ACTIVE MOLECULE, KEY IN COLLAGEN REGENERATION


- UNDER-CONTROL INFLAMMATION PROCESS
 - HIGH BIOCOMPATIBILITY THANKS TO MAXIMIZED CONTACT SURFACE
 - ADAPTED SIZE & SHAPE OF PDLLA PARTICLE
 - High tolerance & excellent tissue compatibility
 - Great dispersibility & Gradual degradation for controlled collagen product
 - 2 concentrations & sizes of molecule, adapted for injection in different layers
- schema taille & niveau d'injection



SPECIFIC MOLECULAR STRUCTURE



FOR A SPHERICAL & POROUS PARTICLE STRUCTURE FOR SUSTAINED REGENERATIVE STIMULATION




Outer : spherical and foamy shape
Minimizing the damage on surrounding tissues
(vs harsh surface of PLLA)

Inner: porous and reticular structure
→ Higher durability for gradual degradation
→ Controlled & slow tissue augmentation

➤ **MECHANICALLY DISPERSIBLE MOLECULE**

PDLLA has a **low Glass Transition Temperature** (Tg - °C) : *Temperature at which PDDL A transitions from a hard & glassy to a soft & rubbery state.*

> *With heat, PDLLA is easily dispersible in the case of side effects*



Spread out the PDLLA particles into smaller masses by pressing down the nodule using fingers.

+ 15% NON-CROSS-LINKED HYALURONIC ACID

GEL CARRIER BASED ON AN ENDOGENOUS MOLECULE

- **Higher safety** thanks to biocompatible molecule to prevent over immune response or allergic solution with better tissue integration (*compared to CMC gel carrier*)
- Facilitate solution **reconstitution**

OPTIMALLY DESIGNED FOR EXCELLENT SAFETY PROFILE & GOOD COLLAGEN INDUCTION

Significantly decreased after 6 months amount of PDLLA particles (Juvelook) in dermis layer




DUAL ACTION FOR COLLAGEN REGENERATION

GRADUAL STIMULATION & PROTECTION

Step 1 : INJECTION IN DEEP DERMIS or SUBCUTANEOUS

JuveLook
LENIANA

PDLLA
Gel carrier
(HA)



Step 2 : CONTROLLED REACTIVE PROCESS



M1 Macrophages
Pro-inflammation

PDLLA is recognized as foreign body by M1 macrophages which start immune body reaction to absorb the PDLLA particles.

Step 3 : REGENERATIVE PHASE

Once particles are absorbed: M1 macrophage polarization into M2
→ higher M2/M1 ratio



M2 Macrophages
Anti-inflammation


Activation of signaling pathway

↑ IL-10
↑ TGFβ

+




Stimulation of proliferation of AD-MSCs
(Adipose-derived mesenchymal stem cells)



Differentiation of new fibroblasts
& production of new collagen

↑ NEW COLLAGEN type I & III
↑ NEW ELASTIN
↑ DERMIS DENSITY



Inhibition of NF-kB expression
(inflammatory pathway)

↓ collagenases
↓ ROS (oxidative stress)

**STIMULATION OF
COLLAGEN & ELASTIN**



**PROTECTION OF
COLLAGEN & ELASTIN**




PROVEN BY SCIENCE

Stimulation & Protection of Collagen and Elastin





**PROTECTION OF COLLAGEN
DUE TO REDUCTION OF NF-κB**



**STIMULATION OF NEW COLLAGEN
& ELASTIN PRODUCTION**



HIGHER FIBERS DENSITY



*Purple stains : Increased amount of collagen
6 months after intradermal injection in of PDLLA (J)

*Source: SAS dermatologic clinic research

(Masson trichrome)

(1) Oh, Seyeon et al. "Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin." *Antioxidants (Basel, Switzerland)* vol. 12,6 1204. 1 Jun. 2023, doi:10.3390/antiox12061204

(2) Oh, Seyeon et al. "Poly-D,L-Lactic Acid Stimulates Angiogenesis and Collagen Synthesis in Aged Animal Skin." *International journal of*


JUVELOOK REFINE & TIGHTEN



- **PDLLA 42.5mg + free HA 7.5mg**
- Particle size : 20 ~ 40 µm
- Injection in deep **dermis**
- For patients with slight ageing & damaged skin quality

En attente etude Clinique %

SKIN QUALITY REJUVENATION – NATURAL RESULTS LASTING TO 12-16 MONTHS



Full face including :
forehead

Tear trough

Peri-oral

Neck

↗ Homogenization of skin texture (fines lines, pores, atrophic acne scars, pigmentation & skin tone)

+92,3% of acne scars still improved at 3 months

-50% of pore size at 3 months

↗ Tightening (elasticity & bouncy skin)

Visible results at 15 days

Optimized at 8 weeks

3 SESSIONS SPACED OUT 6 WEEKS FOR GRADUAL REGENERATION



PER SESSION



1 vial of JUVELOOK
+ 6 CC of distilled water, water for injection or saline solution
including 1 CC lidocaine (optional – to be added before the procedure)

Recommended needle size : 30 -31G, 4 mm

Cannula 25G to 27G – 50 mm is recommended for the tear trough


Dilution tips at the end of the brochure

LENISNA CONTOUR & LIFT



- **PDLLA 170 mg + free HA 30 mg**
- Particule size : **40 ~ 80 µm**
- Injection in **subcutaneous tissue**
- For patient with skin **laxity, sagging & lost of volume**

VOLUME RESTORATION & CONTOURING – NATURAL RESULTS LASTING TO 18 -24 MONTHS



Face including :

- Forehead,
- temples
- Nasolabial folds,
- marionette lines
- Cheek area
- Jawline (for lifting effect)

Décolleté

+ BODY INDICATION

↗ Skin density (improvement of crepey skin & restoration of lost volume)

En attente % étude cl

↗ Dermis quality (firmness & elasticity)

↗ Anchoring dermal-subcutaneous tissue

→ For a lifting effect with reduction of deep folds

94,3% pf patients still corrected at 6 MONTHS *

88,7% at 12 MONTHS *

3 SESSIONS SPACED OUT 8 WEEKS FOR GRADUAL REGENERATION



PER SESSION



1 vial of LENISNA
+ 10CC or 16 CC of saline solution depending on results to achieve
including 2 CC lidocaine (optional – to be added before the procedure)

Recommended injection with cannula - 22G to 25G, 40 – 50 mm


Dilution tips at the end of the brochure

*Single-center, randomized, double-blind, controlled clinical trial evaluating the wrinkle improvement efficacy and safety of a PLA filler in the nasolabial folds

LENISNA & JUVELOOK PROCEDURE & SAFETY TIPS




1 RECONSTITUTION
WITH WATER FOR INJECTION/ DISTILLED WATER / SALINE
SOLUTION
6 CC IN THE VIAL




2 – option 1 PRODUCT DISPERSION

- OPTION 1 : 24 hours before injection : Shake by hand & leave at room temperature



2 – option 2

- OPTION 2 – at least 30 min before injection : Mix with a vortex.



3 JUST BEFORE INJECTION

Only for Lenisna : additional dilution With 4 to 10 CC in a 20 ml syringe for a total amount of 10/16 CC for face or 20 CC for body

Then mix for 10 minutes by hand or using a vortex.
Optional – mix with 1-2 CC of lidocaine & Shake again



4 INJECTION PROCEDURE

+ IMMEDIATELY AFTER INJECTION: Massage the area to help disperse the product.



NCTF 135 HA, UNIQUE REGENERATIVE SOLUTION

- > 60 essential ingredients to the skin stimulation & metabolism, including amino acids, nucleosides, vitamins, etc. supporting the production of new collagen
- > Immediate glow & continuous support to skin stimulation
- > Complementary approach

| BEFORE & AFTER
GALLERY

JUVELOOK & LENISNA TAKE AWAY



- A UNIQUE TECHNOLOGY WITH A DUAL APPROACH OF COLLAGEN : PDDLA + HA CARRIER
 - HIGH CONTROLLED STIMULATION - SLOW DEGRADATION
 - HIGH TOLERANCE & EXCELLENT TISSUE INTEGRATION
- A range of 2 products tailored to each patient's aging grade and injection depth
- DISPERSIBLE BY HEAT

	JUVELOOK	LENISNA	ART FILLER®
Immediate volumization	-	● ● ● ●	● ● ● ●
Regeneration	● ● ● ●		● ● ● ●
Durability of results	● ● ● ●		● ● ● ●
Mode of action	Collagen induction		Mechanical filling
Timeframe	Gradual – visible results after 15 days		Immediate
Protocole	3 sessions spaced out 6 weeks *	3 sessions spaced out 8 weeks *	1 session
Results & benefits	Tightening & skin quality	Skin density (restoration of volume) & dermis quality	Filled wrinkles, plump & contour definition

+ Skin quality with NCTF® 135 HA **

BEAUTY IS AN ART, WE MADE IT A SCIENCE

www.fillmed.com

Laboratoires FILL-MED - Registered Trademark - 38 cours Albert 1^{er} - 75008 Paris - Tel. : +33 (0)1 88 40 03 10

* Number of sessions to be adjusted depending on the patient's biological response ** Not in the same session
JUVELOOK, LENISNA & NCTF® 135 HA are injectable medical devices. For safety information, please refer to the instructions for use of each product. Vigilance contact (notification of an adverse event): vigilance@fillmed.com.